OR WAIT 15 SECS
Curida entered into a partnership with René Bommer, PhD, founder and owner of pharmAccel Consulting.
Curida, a contract development and manufacturing organization (CDMO) based in Norway, has partnered with René Bommer, PhD, who is a nasal spray expert.
Bommer is the founder and owner of pharmAccel Consulting. He also chairs the annual Nasal Drug Delivery conference and is a member of the jury panel at CPhI Pharma Awards. Curida says this new collaboration will strengthen the company’s development services.
Curida acquired a Takeda nasal spray manufacturing facility in July 2015. Curida’s cGMP compliant laboratory service includes performance characterization studies for nasal and inhalation drug products and other dosage forms provided with a delivery device, such as ophthalmic or topical products.
For the development of generic products, Curida can perform in-vitro bioequivalence studies and is responsible for the relevant CMC documentation for submission to the authorities. In addition to physical device performance characterization, Curida develops and validates the microbiological protocols and assesses the microbiological integrity of the product during shelf life and in particular, during a drug’s in-use period.